89Zr-daratumumab
Showing 1 - 25 of 387
Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)
Recruiting
- Multiple Myeloma
- 89Zr-daratumumab PET/CT
-
Irvine, CaliforniaHoag Memorial Hospital Presbyterian
Aug 1, 2022
Multiple Myeloma Trial in New York (drug, device, other)
Completed
- Multiple Myeloma
- 89Zr-daratumumab
- +2 more
-
New York, New YorkMemorial Slaon-Kettering Cancer Center
Jul 9, 2021
Multiple Myeloma, Plasma Cell Myeloma Trial in San Francisco (drug, procedure, other)
Not yet recruiting
- Multiple Myeloma
- Plasma Cell Myeloma
- Zirconium Zr 89-DFO-YS5
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 26, 2023
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- +2 more
- (no location specified)
May 14, 2023
Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)
Available
- Clear Cell Renal Cell Carcinoma
- 89Zr-DFO-girentuximab
-
Los Angeles, CaliforniaUCLA
Oct 12, 2023
Prostate Cancer Trial in New York (89Zr- DFO-MSTP2109A, 89Zr DFO-MSTP2109A)
Active, not recruiting
- Prostate Cancer
- 89Zr- DFO-MSTP2109A
- 89Zr DFO-MSTP2109A
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 1, 2023
Multiple Myeloma Trial in Wuxi (89Zr-NY008)
Recruiting
- Multiple Myeloma
-
Wuxi, Jiangsu, ChinaAffiliated Hospital of Jiangnan University
Dec 15, 2022
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Recruiting
- Neurofibromatosis 2
- Bevacizumab Zirconium Zr-89
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Jan 5, 2023
Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Amsterdam (89Zr-DFO*-trastuzumab PET scan)
Recruiting
- Breast Cancer
- +5 more
- 89Zr-DFO*-trastuzumab PET scan
-
Amsterdam, Noord-Holland, NetherlandsAmsterdamUMC
Jul 12, 2023
Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in
Not yet recruiting
- Metastatic Triple-Negative Breast Carcinoma
- 89Zr-atezolizumab PET/CT
- (no location specified)
Feb 22, 2023
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Panitumumab
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 16, 2023
Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)
Recruiting
- Large B-cell Lymphoma
- DLBCL
- 89Zr-DFO-REGN3767
- PET/CT
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 3, 2022
Amyotrophic Lateral Sclerosis Trial (89Zr-DFO-AP-101)
Not yet recruiting
- Amyotrophic Lateral Sclerosis
- (no location specified)
Jul 26, 2023
NSCLC Trial in Heidelberg (89Zirconium-M7824, M7824)
Terminated
- Non-Small Cell Lung Cancer
- 89Zirconium-M7824
- M7824
-
Heidelberg, Victoria, AustraliaAustin Health
Jan 13, 2023
Advanced Solid Tumor, Metastatic Solid Tumor Trial (89Zr?DFO?REGN5054, cemiplimab)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- (no location specified)
Aug 5, 2022
Melanoma, Renal Cell Carcinoma Trial in Hull (Zirconium 89Zr crefmirlimab berdoxam)
Recruiting
- Melanoma
- Renal Cell Carcinoma
- Zirconium 89Zr crefmirlimab berdoxam
-
Hull, United KingdomCastle Hill Hospital
Feb 15, 2023
Rheumatoid Arthritis Trial in San Francisco (89Zr-DFO-CZP)
Suspended
- Rheumatoid Arthritis
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jun 7, 2022
Lung Cancer, Colorectal Cancer Trial in Saskatoon (50 mg 89Zr-DFO-Nimotuzumab, 1 mg 89Zr-DFO-Nimotuzumab)
Recruiting
- Lung Cancer
- Colorectal Cancer
- 50 mg 89Zr-DFO-Nimotuzumab
- 1 mg 89Zr-DFO-Nimotuzumab
-
Saskatoon, Saskatchewan, CanadaRoyal University Hospital
May 18, 2022
Cervical Cancer, Colorectal Cancer, Esophageal Cancer Trial (89Zr-DFO-girentuximab)
Not yet recruiting
- Cervical Cancer
- +13 more
- (no location specified)
Sep 28, 2022
Advanced Solid Tumor Trial in Amsterdam, Groningen (89Zr-S095012 tracer and S095012 will be administered via an IV infusion)
Recruiting
- Advanced Solid Tumor
- 89Zr-S095012 tracer and S095012 will be administered via an IV infusion
-
Amsterdam, Netherlands
- +1 more
Dec 9, 2022
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Tumors Trial (BI 764532, [89Zr]Zr-BI 764532)
Not yet recruiting
- Small Cell Lung Carcinoma (SCLC)
- Neuroendocrine Neoplasms
- BI 764532
- [89Zr]Zr-BI 764532
- (no location specified)
Jul 31, 2023